Techniques to evaluate surfactant activity for a personalized therapy of RDS neonates

Biomed J. 2021 Dec;44(6):671-677. doi: 10.1016/j.bj.2021.11.001. Epub 2021 Nov 7.

Abstract

According to both European and American Guidelines, preterm neonates have to be treated by nasal continuous air pressure (CPAP) early in the delivery room. The administration of surfactant should be reserved only for babies with respiratory distress syndrome (RDS) with increased oxygen requirement, according to different thresholds of FiO2. However, these oxygenation thresholds do not fully take into consideration the lung physiopathology and mechanics or the lung surfactant biology of RDS neonates. Since surfactant replacement therapy (SRT) seems to be more effective if it is initiated within the first 3 hours after birth, the use of a reliable bench-to-bedside biological test able to predict as soon as possible the necessity of SRT will help optimise individualised therapies and personalise the actual collective strategy used to treat RDS neonates. With this in mind, in the present review several quantitative and qualitative biological tests to assess the surfactant status in RDS neonates are introduced as potential candidates for the early prediction of SRT requirement, summarising the state-of-the-art in the evaluation of surfactant activity.

Keywords: CPAP failure; Lung surfactant; RDS prediction.

Publication types

  • Review

MeSH terms

  • Continuous Positive Airway Pressure
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Pulmonary Surfactants* / therapeutic use
  • Respiratory Distress Syndrome, Newborn* / drug therapy
  • Surface-Active Agents / therapeutic use

Substances

  • Pulmonary Surfactants
  • Surface-Active Agents